Patent Supporting Gout and Autosomal Dominant Polycystic Kidney Disease ProgramsCALGARY, Alberta, April 28, 2025 (GLOBE ...

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical ...

Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

The Primary objective is to assess the effectiveness of SAP-001 in lowering serum urate levels in gout patients that are refractory to standard-of-care Xanthine Oxidase Inhibitor (XOI) therapy.

XORTX Therapeutics Inc ( ($TSE:XRTX) ) has issued an announcement. XORTX Therapeutics Inc. has received a notification from the Nasdaq Stock ...

During my doctoral studies, I have synthesized several libraries of heterocyclic molecules with anti-tubulin and xanthine oxidase inhibitory activity that can be useful in cancer and gout, ...